Physician profile
Omer E Ibrahim
NPI 1871869438
$312,688.39
in general payments reported to CMS, 2019-2025
37 companies · $11K in 2025
The $11K reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,118 · 2021: $3,495 · 2022: $87K · 2023: $117K · 2024: $78K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $147K · Consulting Fee: $48K · Travel and Lodging: $6,645 · Food and Beverage: $4,699 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $146,600.00 |
| Consulting Fee | $48,346.67 |
| Travel and Lodging | $6,645.42 |
| Food and Beverage | $4,698.99 |
| Education | $256.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $217,260.45 | 2019-2025 | Olumiant, Taltz, Jaypirca |
| Abbvie INC. | $60,534.80 | 2019-2025 | |
| Allergan, INC. | $18,819.70 | 2019-2022 | |
| Galderma Laboratories, L.P. | $7,654.21 | 2019-2025 | Nemluvio |
| Solta Medical, A Division of Bausch Health US, LLC | $4,363.53 | 2019-2021 | |
| Merz North America, INC. | $747.97 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $433.20 | 2019-2023 | |
| Pfizer INC. | $343.72 | 2019-2025 | |
| Janssen Biotech, INC. | $289.28 | 2021-2025 | Tremfya |
| Genzyme Corporation | $240.29 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $230.70 | 2020-2021 | |
| Amgen INC. | $213.67 | 2019-2023 | Otezla |
| Regeneron Healthcare Solutions, INC. | $181.72 | 2019-2025 | Dupixent |
| Celgene Corporation | $171.02 | 2019 | |
| Leo Pharma INC. | $142.61 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omer Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.